Markets:

Overview

News

Currencies

International

Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

79.71 -1.67 (-2.05%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗

Today 11:18 EST

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

Today 11:12 EST

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Via The Motley Fool

Topics Regulatory Compliance

What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally ↗

February 26, 2026

MDU Resources Group supplies regulated utilities and construction services across the U.S., with consistent revenue and a stable dividend.

Via The Motley Fool

Topics Energy

GeneDx Holdings Corp (NASDAQ:WGS) Reports Mixed Q4 2025 Results, Stock Falls Despite Strong 2026 Outlook ↗

February 23, 2026

Via Chartmill

GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell? ↗

February 26, 2026

AI-powered health intelligence firm GeneDx Holdings reported a notable insider sale as it advances its clinical data analytics platform.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

GeneDx to Participate in Upcoming Investor Conferences

February 25, 2026

From GeneDx

Via Business Wire

GeneDx (WGS) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

GeneDx (WGS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Artificial Intelligence Earnings

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

February 23, 2026

From GeneDx

Via Business Wire

Power Solutions Stock Up 140% as $6.36 Million Exit Follows 62% Sales Surge ↗

February 16, 2026

Power Solutions International designs and manufactures advanced engines and power systems for industrial and transportation markets.

Via The Motley Fool

Topics Energy Regulatory Compliance

Freshworks Falls 60% in a Year as $7.5 Million Sale Shrinks Stake to 3.1% of This Portfolio's Assets ↗

February 16, 2026

This SaaS firm delivers cloud-based business software worldwide, focusing on subscription-driven customer and IT service solutions.

Via The Motley Fool

Topics Regulatory Compliance

Air Lease Stock Up 43% as Investor Trims $6.9 Million Stake Despite $1 Billion Profit Year ↗

February 16, 2026

Air Lease Corporation provides global airlines with commercial jet leasing, sales, and fleet management services across a diverse portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Five9 Stock Down 60% This Past Year, but One Investor Just Lifted Stake With $3.5 Million Buy ↗

February 16, 2026

Five9 delivers cloud-based contact center software for enterprises, serving clients across finance, healthcare, and technology sectors.

Via The Motley Fool

Freshworks Stock Down 60% in One Year as Revenue Jumps 16% and One Investor Sells $7 Million in Shares ↗

February 16, 2026

Freshworks delivers cloud-based SaaS solutions for customer engagement, IT service management, and business process automation.

Via The Motley Fool

Topics Regulatory Compliance

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

February 11, 2026

From GeneDx

Via Business Wire

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

February 03, 2026

From GeneDx

Via Business Wire

The Great Rotation: Small-Caps Stand Tall as AI Exhaustion Triggers Tech Rout

January 29, 2026

The stark divide in the financial markets reached a fever pitch today, January 29, 2026, as the long-anticipated "Great Rotation" finally appeared to take hold. While the tech-heavy Nasdaq Composite...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Great Rotation of 2026: Why Wall Street is Abandoning Big Tech for Main Street Small Caps

January 28, 2026

The dawn of 2026 has brought a seismic shift to global equity markets, as the long-anticipated "Great Rotation" finally takes hold. After nearly three years of dominance by a handful of mega-cap...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great AI Pivot: From Massive Build-Out to the Era of Operational ROI

January 27, 2026

As of January 27, 2026, the global financial markets are witnessing a profound transformation in the artificial intelligence narrative. While 2023 and 2024 were defined by a "land grab" for...

Via MarketMinute

Topics Artificial Intelligence Economy Workforce

The Great Rotation: Wall Street’s ‘Earnings Handoff’ Moves from Silicon Valley to Main Street

January 26, 2026

As of January 26, 2026, the financial landscape has undergone a seismic shift, marking the definitive end of the "Magnificent 7" era of uncontested dominance. For the first time in decades, the baton...

Via MarketMinute

Topics Artificial Intelligence ETFs Earnings

The Great Rotation: Small-Caps Set to Outpace ‘Magnificent 7’ in Historic Earnings Handoff

January 26, 2026

As of January 26, 2026, the long-standing hierarchy of the U.S. equity markets is undergoing its most significant transformation since the post-pandemic recovery. For the first time in years, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 25, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 24, 2026

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Via The Motley Fool

The Great Rotation of 2026: Why Wall Street is Betting Big on the Russell 2000

January 22, 2026

As of January 22, 2026, the financial landscape is witnessing a historic shift. After nearly two years of mega-cap technology dominance driven by the artificial intelligence boom, the "Great Rotation"...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026

From Halper Sadeh LLC

Via Business Wire

The Great Rotation: Small-Cap Stocks Surge in Early 2026 as Market Leadership Broadens

January 13, 2026

As of January 13, 2026, the financial landscape has undergone a dramatic transformation, marked by a decisive "regime shift" that many Wall Street analysts are calling the "Great Rotation." For the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great Rotation: Small-Caps Log Longest Winning Streak Against S&P 500 Since 2019

January 12, 2026

As of mid-January 2026, the U.S. equity markets are witnessing a historic recalibration that few analysts predicted eighteen months ago. The Russell 2000 index, the benchmark for American small-cap...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

January 12, 2026

From GeneDx

Via Business Wire

GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

January 08, 2026

From GeneDx

Via Business Wire

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

January 07, 2026

From GeneDx

Via Business Wire

GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

January 06, 2026

From GeneDx

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.